Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey. Επικοινωνία Submitted by Δημήτρης Σπάχος on Παρ, 12/04/2020 - 20:54
